Introduction

Quest Diagnostics recently raised its 2026 profit and revenue forecasts. This update reflects a resilient diagnostic testing demand across both routine and advanced clinical categories. Consequently, the New Jersey-based provider reported first-quarter results that surpassed previous Wall Street expectations. Shares rose significantly as investors reacted to the positive financial outlook.

Trends in Diagnostic Testing Demand

Healthcare providers are currently navigating a phase of post-pandemic normalization. Therefore, many companies lean on hospital laboratory management deals to maintain steady volumes. Quest recorded a 9.4% revenue increase for its largest business segment. Furthermore, organic requisition volumes increased by over 10% during this period. This growth persists even while the industry faces sustained reimbursement pressures and rising labor costs.

Growth in Advanced Diagnostics

Beyond routine screenings, advanced diagnostic tools show substantial market growth. Specifically, blood tests used to identify Alzheimer's disease are gaining significant traction. Also, tests for cardiometabolic and endocrine conditions reported double-digit revenue increases. These trends highlight a growing clinical focus on early detection of chronic conditions. The company expects to continue this momentum throughout the fiscal year.

Frequently Asked Questions

Q1: Why did Quest Diagnostics raise its 2026 forecast?

The company cited resilient demand for routine diagnostic testing and significant growth in advanced diagnostics as primary drivers for the upgraded outlook.

Q2: Which specialty testing areas showed the most growth?

Quest reported double-digit revenue growth in advanced diagnostics, specifically in blood tests for Alzheimer's, cardiometabolic conditions, and endocrine disorders.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Quest Diagnostics raises full-year forecast, posts strong quarter on testingdemand - ETHealthworld


2. Quest Diagnostics Investor Relations. (2026). First Quarter 2026 Performance Report.


3. Reuters. (2026). Diagnostic Providers Navigate Post-Pandemic Normalization.